Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RYTM | Rhythm Pharmaceuticals, Inc.

Index	RUT	P/E	-	EPS (ttm)	-3.29	Insider Own	0.10%	Shs Outstand	56.87M	Perf Week	-5.80%
Market Cap	1.31B	Forward P/E	-	EPS next Y	-2.29	Insider Trans	-27.15%	Shs Float	56.66M	Perf Month	-8.33%
Income	-182.20M	PEG	-	EPS next Q	-0.75	Inst Own	108.16%	Short Float / Ratio	18.80% / 13.10	Perf Quarter	23.43%
Sales	43.80M	P/S	29.82	EPS this Y	-147.60%	Inst Trans	29.07%	Short Interest	10.65M	Perf Half Y	37.62%
Book/sh	3.21	P/B	7.24	EPS next Y	29.30%	ROA	-51.10%	Target Price	38.22	Perf Year	-3.53%
Cash/sh	4.51	P/C	5.15	EPS next 5Y	-9.00%	ROE	-76.90%	52W Range	15.50 - 34.99	Perf YTD	-20.23%
Dividend	-	P/FCF	-	EPS past 5Y	-4.20%	ROI	-52.70%	52W High	-33.61%	Beta	1.63
Dividend %	-	Quick Ratio	6.00	Sales past 5Y	-	Gross Margin	88.20%	52W Low	49.87%	ATR	1.17
Employees	177	Current Ratio	6.20	Sales Q/Q	111.00%	Oper. Margin	-	RSI (14)	40.90	Volatility	4.72% 4.79%
Optionable	Yes	Debt/Eq	0.43	EPS Q/Q	8.00%	Profit Margin	-	Rel Volume	0.77	Prev Close	24.03
Shortable	Yes	LT Debt/Eq	0.43	Earnings	Aug 01 BMO	Payout	-	Avg Volume	812.89K	Price	23.23
Recom	1.70	SMA20	-8.58%	SMA50	0.88%	SMA200	3.41%	Volume	626,122	Change	-3.33%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy	$22 → $27
Jan-18-23	Resumed	Canaccord Genuity	Buy	$52
Aug-08-22	Upgrade	Goldman	Neutral → Buy	$28
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $20
Jun-17-22	Reiterated	Needham	Buy	$40 → $25
Mar-02-22	Resumed	Stifel	Buy	$23
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy	$15
Dec-08-21	Initiated	Wells Fargo	Overweight	$30
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$50 → $15
Sep-14-21	Resumed	Goldman	Neutral	$14
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform	$33 → $17
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral	$27 → $33
Jan-08-20	Initiated	Goldman	Sell	$18
Jul-12-19	Upgrade	Stifel	Hold → Buy	$34
Jul-08-19	Initiated	Canaccord Genuity	Buy	$35
Mar-13-19	Initiated	Ladenburg Thalmann	Buy	$43
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy	$36 → $42
Jun-15-18	Reiterated	Needham	Buy	$32 → $36

Show Previous Ratings

Sep-19-23 08:01AM	Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity (GlobeNewswire)
Sep-08-23 05:01PM	EVP Jennifer Lee Sells 6,166 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
07:59AM	Rhythm Pharmaceuticals Announces Update to September Conference Participation (GlobeNewswire)
Sep-06-23 07:59AM	Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome (GlobeNewswire)
08:00AM	Loading…
Aug-28-23 08:00AM	Rhythm Pharmaceuticals to Present at Investor Conferences in September (GlobeNewswire)
Aug-07-23 08:00AM	Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France (GlobeNewswire)
Aug-04-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Aug-03-23 06:07AM	Need To Know: Analysts Are Much More Bullish On Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenues (Simply Wall St.)
Aug-01-23 08:35AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +27.52%
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Jul-19-23 08:00AM	Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome (GlobeNewswire)
Jul-18-23 08:00AM	Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 (GlobeNewswire)
Jul-17-23 06:00AM	Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 (GlobeNewswire) +5.34%
Jul-14-23 04:40PM	These 2 Biotech Stocks Are Most Likely to Be Acquired, Says Needham and They Have Over 60% Upside Potential (TipRanks)
04:01PM	Loading…
Jul-13-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Jun-29-23 12:45PM	What Will Amgen Buy Next? (Motley Fool) -8.04%
Jun-17-23 02:01PM	Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023 (GlobeNewswire)
Jun-07-23 08:00AM	Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-06-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Jun-05-23 08:46AM	Investors bid Rhythm Pharmaceuticals (NASDAQ:RYTM) up US$87m despite increasing losses YoY, taking one-year return to 428% (Simply Wall St.)
May-22-23 08:00AM	Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries (GlobeNewswire)
May-09-23 08:11AM	Some Shareholders Feeling Restless Over Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) P/S Ratio (Simply Wall St.)
May-08-23 08:00AM	Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency (GlobeNewswire)
May-05-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
May-04-23 10:05AM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2023 Earnings Call Transcript (Insider Monkey) -11.18%
May-02-23 08:45AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.27%
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Apr-26-23 10:02AM	Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-25-23 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks)
07:00AM	Loading…
Apr-24-23 07:00AM	Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome (GlobeNewswire)
Apr-18-23 08:00AM	Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023 (GlobeNewswire)
Apr-12-23 07:23AM	We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely (Simply Wall St.)
Apr-10-23 08:00AM	Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-06-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Mar-27-23 08:00AM	Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide (GlobeNewswire)
Mar-08-23 10:02PM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Mar-02-23 09:20PM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.84%
05:32AM	Rhythm Pharmaceuticals Full Year 2022 Earnings: US$3.48 loss per share (vs US$1.40 loss in FY 2021) (Simply Wall St.)
Mar-01-23 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.33%
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:45AM	Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics (GlobeNewswire)
Feb-21-23 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023 (GlobeNewswire) -6.39%
Feb-08-23 08:00AM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) -5.42%
Jan-23-23 08:00AM	Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome (GlobeNewswire)
Jan-09-23 08:45AM	3 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool) -7.10%
Jan-05-23 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +6.62%
Dec-30-22 12:46AM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-28-22 11:58PM	12 Best Performing NASDAQ Stocks in 2022 (Insider Monkey)
10:15PM	12 Best Performing Biotech Stocks in 2022 (Insider Monkey)
Dec-14-22 06:23AM	Shareholders have faith in loss-making Rhythm Pharmaceuticals (NASDAQ:RYTM) as stock climbs 7.8% in past week, taking one-year gain to 190% (Simply Wall St.)
Dec-07-22 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Dec-01-22 08:00AM	Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference (GlobeNewswire)
Nov-21-22 08:00AM	Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome (GlobeNewswire) -9.02%
Nov-11-22 09:32AM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Lifting Their Price Targets (Simply Wall St.)
Nov-10-22 09:02AM	Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Intrinsic Value Is Potentially 17% Below Its Share Price (Simply Wall St.) +15.10%
Nov-08-22 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology (GlobeNewswire)
07:00AM	Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Nov-07-22 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Nov-03-22 08:00AM	Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Societys Annual Meeting at ObesityWeek® (GlobeNewswire) +6.20%
Nov-02-22 07:30AM	Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023 (GlobeNewswire) -12.53%
Nov-01-22 08:00AM	Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA (GlobeNewswire)
Oct-25-22 10:02AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline (Zacks)
08:00AM	Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022 (GlobeNewswire)
Oct-18-22 10:21AM	Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-12-22 08:00AM	Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022 (GlobeNewswire)
Oct-06-22 04:02PM	Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Sep-23-22 08:00AM	Rhythm Pharmaceuticals Announces Publication of Childrens Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS) (GlobeNewswire) -10.35%
Sep-19-22 04:01PM	Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering (GlobeNewswire)
08:00AM	Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022 (GlobeNewswire)
07:44AM	Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) large institutional owners must be happy as stock continues to impress, up 4.0% over the past week (Simply Wall St.)
Sep-14-22 10:20PM	Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering (GlobeNewswire) +24.40%
04:01PM	Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering (GlobeNewswire)
Sep-07-22 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Sep-06-22 04:01PM	Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome (GlobeNewswire) -13.97%
Sep-01-22 08:00AM	Rhythm Pharmaceuticals to Present at Investor Conferences in September (GlobeNewswire) +12.12%
Aug-28-22 09:29AM	3 Healthcare Stocks That Are Beating the Market (Motley Fool)
Aug-12-22 09:55AM	After Golden Cross, Rhythm Pharmaceuticals, Inc. (RYTM)'s Technical Outlook is Bright (Zacks) +9.33%
Aug-08-22 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
03:01PM	Can Rhythm Pharmaceuticals Keep Up This Tempo? (TheStreet.com)
06:15AM	Industry Analysts Just Upgraded Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts By 60% (Simply Wall St.)
Aug-03-22 08:00AM	Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire) +23.71%
Aug-02-22 03:51PM	Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today (Motley Fool) +13.82%
01:46PM	Rhythm Pharma Outlines Robust Start To Newly Approved Drug For Genetic Condition (Benzinga)
08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Jul-28-22 08:00AM	Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 (GlobeNewswire) +14.50%
Jul-27-22 10:01AM	Morphic Holding, Inc. (MORF) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-26-22 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-22-22 08:39AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome (GlobeNewswire) -10.78%
Jul-21-22 04:03PM	Rhythm Has Tripled In A Week And Quintupled Since May Here's Why (Investor's Business Daily) +11.66%
Jul-20-22 08:00AM	Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France (GlobeNewswire) +24.86%
Jul-18-22 06:00AM	NICE Recommends Rhythms IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency (GlobeNewswire) +13.69%
Jul-13-22 12:15PM	Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate (Zacks) +31.48%
09:40AM	Rhythm Pharmaceuticals, Inc. (RYTM) Surges 42.2%: Is This an Indication of Further Gains? (Zacks)
Jul-12-22 09:12AM	Rhythm Pharma's Setmelanotide Shows Encouraging Action In Hypothalamic Obesity Study (Benzinga) +42.22%
07:00AM	Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity (GlobeNewswire)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstrom syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Jennifer Kayden	EVP, Head of North America	Sep 05	Option Exercise	6.80	4,519	30,729	7,813	Sep 07 05:48 PM
Lee Jennifer Kayden	EVP, Head of North America	Sep 05	Sale	28.05	6,166	172,958	1,647	Sep 07 05:48 PM
Lee Jennifer Kayden	EVP, Head of North America	Aug 09	Option Exercise	6.80	1,718	11,682	5,012	Aug 09 04:30 PM
Lee Jennifer Kayden	EVP, Head of North America	Aug 09	Sale	24.66	1,718	42,366	3,294	Aug 09 04:30 PM
Lee Jennifer Kayden	EVP, Head of North America	Aug 07	Option Exercise	6.80	8,591	58,419	14,517	Aug 09 04:30 PM
Lee Jennifer Kayden	EVP, Head of North America	Aug 07	Sale	24.18	11,223	271,347	3,294	Aug 09 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 26	Sale	17.64	930	16,405	8,418	Jul 28 09:01 PM
Smith Hunter C	Chief Financial Officer	Jun 16	Option Exercise	6.88	2,000	13,760	61,406	Jun 21 04:05 PM
Roberts William T.	Chief Accounting Officer	Mar 29	Sale	17.50	912	15,960	7,872	Mar 31 09:38 PM
Mazabraud Yann	EVP, Head of International	Feb 14	Sale	27.03	1,177	31,814	3,827	Feb 16 04:05 PM
Smith Hunter C	Chief Financial Officer	Feb 14	Sale	26.87	702	18,863	59,406	Feb 14 08:59 PM
Chien Jennifer	EVP, Head of North America	Feb 14	Sale	26.87	635	17,062	4,940	Feb 14 08:59 PM
Shulman Joseph	Chief Technical Officer	Feb 14	Sale	26.87	554	14,886	3,741	Feb 14 09:00 PM
Mazabraud Yann	EVP, Head of International	Feb 09	Sale	27.66	1,548	42,818	2,988	Feb 13 05:03 PM
Smith Hunter C	Chief Financial Officer	Feb 09	Sale	27.66	1,398	38,669	57,779	Feb 13 05:03 PM
Chien Jennifer	EVP, Head of North America	Feb 09	Sale	27.66	1,192	32,971	3,556	Feb 13 05:04 PM
Roberts William T.	Chief Accounting Officer	Feb 09	Sale	27.66	959	26,526	6,294	Feb 13 05:02 PM
Shulman Joseph	Chief Technical Officer	Feb 09	Sale	27.66	921	25,475	2,742	Feb 13 05:00 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 09	Sale	27.66	834	23,068	6,151	Feb 13 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RYTM | Rhythm Pharmaceuticals, Inc.

Upgrade your FINVIZ experience